Goldman Sachs Starts Phathom Pharmaceuticals (PHAT) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Evercore ISI Starts Phathom Pharmaceuticals (PHAT) at Outperform
November 19, 2019 8:27 PM ESTEvercore ISI analyst Umer Raffat initiates coverage on Phathom Pharmaceuticals (NASDAQ: PHAT) with a Outperform rating.
For an analyst ratings summary and ratings history on Phathom Pharmaceuticals click here. For more ratings news on Phathom Pharmaceuticals click here.
Shares of Phathom Pharmaceuticals closed at $24.27 yesterday.
... MoreNeedham & Company Starts Phathom Pharmaceuticals (PHAT) at Buy, Street High $40 PT
November 19, 2019 7:45 AM ESTNeedham & Company analyst Alan Carr initiates coverage on Phathom Pharmaceuticals (NASDAQ: PHAT) with a Buy rating and a price target of $40.00.
The analyst comments "Phathom is developing vonoprazan, a novel oral potassium-competitive acid blocker (PCAB) for the treatment of Erosive Esophagitis... More
